Please login to the form below

Not currently logged in
Email:
Password:

MNK-795

This page shows the latest MNK-795 news and features for those working in and with pharma, biotech and healthcare.

Mallinckrodt offers $1.3bn for Cadence Pharma

company.". Mallinckrodt is also active in the analgesia sector and last year won priority review status from the FDA for MNK-795, a controlled-release oral formulation of oxycodone and acetaminophen

Latest news

  • FDA grants priority review to pain drug

    Mallinckrodt’s MNK-795 is intended for the management of moderate to severe acute pain. ... Mallinckrodt has won priority review from the US Food and Drug Administration (FDA) for its pain drug MNK-795.

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Viseven

Viseven is a full cycle digital agency with 10 years expertise in developing content for the global pharmaceutical market delivering...

Latest intelligence

InSite Events™ National Pharma Meeting: A Customer Story
How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
Fear or encouragement, which is best to drive behaviour change?
The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...
The unheard, unseen, and uncorrected effects of COVID-19
The disproportionate effects of the pandemic have been highlighted amongst ethnic minorities, so is it likely that ethnic minorities will be more worried about participating? And could this exacerbate inequalities...

Infographics